{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:33:05Z","timestamp":1777858385588,"version":"3.51.4"},"reference-count":46,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["980429"],"award-info":[{"award-number":["980429"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Drugs for psychosis can cause weight gain and metabolic disorders in schizophrenia. Given its partial agonistic activity at histamine receptors, betahistine could shape the effects of drugs for psychosis on weight gain and food intake. This study evaluates the effect of betahistine administration on anthropometric indices and symptoms of schizophrenia in schizophrenic patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This randomized controlled trial was conducted on schizophrenic patients between 2020 and 2022. After stratification based on the type of treatment (olanzapine (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928) or risperidone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928)), patients of each stratum were randomly divided into two groups (betahistine or placebo). The duration of the intervention was 12\u2009weeks. Betahistine was started at 8\u2009mg\/day and gradually increased to 48\u2009mg in 11\u2009days. Anthropometric indices were measured monthly, while fasting blood glucose, lipid profile, TSH, and Positive and Negative Syndrome Scale (PANSS) were assessed at baseline and 12\u2009weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All anthropometric measures improved in patients receiving betahistine, except for increased waist circumference in those receiving olanzapine\u2009+\u2009betahistine. Triglyceride levels were significantly reduced in the olanzapine\u2009+\u2009betahistine subgroup compared to the placebo group (\u221212.14\u2009\u00b1\u200915.49 vs \u22120.28\u2009\u00b1\u20099.31;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021). Moreover, PANSS decreased significantly in all groups during the study, but the difference between groups was not significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The addition of betahistine appears to be well tolerated and positively influences anthropometric indices. These findings suggest that betahistine may help mitigate some of the metabolic side effects of drugs for psychosis, although further research is needed to confirm these effects and to explore the optimal dosage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number:<\/jats:title>\n                    <jats:p>IRCT20191223045870N1 in Iranian Registry of Clinical Trials (https:\/\/irct.behdasht.gov.ir\/).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251346696","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T02:19:32Z","timestamp":1751941172000},"page":"804-814","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of betahistine on weight-related and metabolic measures in patients with schizophrenia treated with olanzapine and risperidone"],"prefix":"10.1177","volume":"39","author":[{"given":"Najmeh","family":"Abbasi Jannatabadi","sequence":"first","affiliation":[{"name":"Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran (Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1526-3765","authenticated-orcid":false,"given":"Maryam","family":"Emadzadeh","sequence":"additional","affiliation":[{"name":"Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran (Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Fayyazi Bordbar","sequence":"additional","affiliation":[{"name":"Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran (Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Ahmad","family":"Mohajeri","sequence":"additional","affiliation":[{"name":"Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran (Islamic Republic of)"},{"name":"Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5743-661X","authenticated-orcid":false,"given":"Mahsa","family":"Nahidi","sequence":"additional","affiliation":[{"name":"Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran (Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S392770"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094112"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2014.07.004"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115626349"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000489"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00751-2"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v11.i10.696"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S225643"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S113099"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618756261"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1049-5"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.11.009"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0571-z"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.47836\/mjmhs.18.s19.28"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.730769"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.914165"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"e_1_3_3_20_1","first-page":"1","article-title":"Most common side effects of clozapine and their management","volume":"18","author":"Iqbal MM","year":"2016","unstructured":"Iqbal MM, Swati S, Aneja A, et al. (2016) Most common side effects of clozapine and their management. Int J Emerg Ment Health 18: 1\u20136.","journal-title":"Int J Emerg Ment Health"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00620"},{"key":"e_1_3_3_22_1","first-page":"137","volume-title":"Advances in Pharmacology","author":"Khokhar JY","year":"2018","unstructured":"Khokhar JY, Henricks AM, Sullivan EDK, et al. (2018) Chapter seven \u2013 unique effects of clozapine: A pharmacological perspective. In: Pasternak GW, Coyle JT (eds.) Advances in Pharmacology. Cambridge, MA: Academic Press, pp. 137\u2013162."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000172994.56028.c3"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05983-9"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104160"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.02.011"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2020.104744"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.54097\/hset.v8i.1140"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03521-7"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbr148"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.766692"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.2582"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S125367"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.3803"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-012-2935-2"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-5079-1"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02138-4"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.05.028"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.5.800a"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-020-00319-x"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61719-X"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.762656"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2007.56-b"},{"key":"e_1_3_3_45_1","article-title":"Prevalence and factors associated of metabolic syndrome in first-treatment drug-na\u00efve schizophrenia patients: A large-scale cross-sectional study","volume":"19","author":"Zhang L","year":"2023","unstructured":"Zhang L, Dai X, Li Y, et al. (2023) Prevalence and factors associated of metabolic syndrome in first-treatment drug-na\u00efve schizophrenia patients: A large-scale cross-sectional study. Early Interv Psychiatry 19: e13565.","journal-title":"Early Interv Psychiatry"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000392"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12631"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251346696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251346696","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251346696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:17Z","timestamp":1777507937000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251346696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1177\/02698811251346696"],"URL":"https:\/\/doi.org\/10.1177\/02698811251346696","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}